Index of Posters and Abstracts



Medical Advocates for Social Justice
Conference Reports, Power-Point Presentations, Abstracts, and Posters from

		XII International HIV Drug Resistance Workshop Los Cabos, Mexico June 10-14, 2003

Main New/Newsworthy Conference Updates Home

Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader 5 .

Conference Report

FULL-TEXT CONFERENCE PDF REPORT
Sex, Drugs, and Viral Escape:
Mascolini, M
IAS Web July 05, 2003
This is a 26,000 word article and may take several minutes to download

Posters, Power-Point Presentations, and Abstracts

Specific ARV Drugs

     Efavirenz

POWERPOINT POSTER
Genetic correlates of phenotypic hypersusceptibility to efavirenz among 446 baseline isolates from five ACTG studies
NS Shulman, RJ Bosch, JW Mellors, et al.
Poster

POWERPOINT POSTER
Mutations in HIV-1 reverse transcriptase associated with hypersusceptibility to non-nucleoside reverse transcriptase inhibitors: impact on virological response to efavirenz-based salvage therapy
V Tozzi, et al
Poster

Low frequency non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant variants contribute to failure of efavirenz-containing regimens in NNRTI-experienced patients with negative standard genotypes for NNRTI mutations
J Mellors, S Palmer, D Nissley, et al.
Abstract

Emtricitabine

PDF POSTER
Characterization of baseline and treatment-emergent resistance mutations following 1 year of therapy on an entirely once a day regimen including emtricitabine
K Borroto-Esoda, J Waters, JB. Quinn, et al
PDF Poster

     Enfuvirtide

PDF POSTER
Baseline and on-treatment gp41 genotype and susceptibility to enfuvirtide (ENF) and T-1249 in a 10-day study of T-1249 in patients failing an ENF-containing regimen (T1249-102)
GD Miralles, Melby, R DeMasi,et al.
PDF Poster

POWER-POINT PRESENTATION
The Relationship between Susceptibility to Enfuvirtide of Baseline Viral Recombinants and Polymorphisms in the Env Region of R5-tropic HIV-1
C. Su, G. Heilek-Snyder, D. Fenger, et al.
Presentation       Abstract

Subgroup analysis of baseline susceptibility and early virological response to enfuvirtide
in the combined TORO studies
P Sista, T Melby, ML Greenberg, et al
Poster

PDF POSTER
Determinants of susceptibility to enfuvirtide map to gp41 in enfuvirtide-naive HIV-1
SA Stanfield-Oakley, J Jeffrey, CB McDanal, et al.
Poster

Mechanisms underlying a sustained CD4 T cell recovery despite the emergence of resistance in antiretroviral-experienced patients on prolonged enfuvirtide treatment
Rodés, JM Benito, et al
Abstract

     GW433908

PDF POSTER
HIV Clinical Isolates Containing Mutations Representative of those Selected after First Line Failure with Unboosted GW433908 Remain Sensitive to Other Protease Inhibitors 19
L Ross , N Parkin, C Chappey, et al
PDF Poster

      Lopinavir

POWERPOINT POSTER
Interpreting resistance to lopinavir/ritonavir in HIV-1 subtype C patients
Z Grossman
Poster

PDF POSTER
Emergence of a novel lopinavir resistance mutation at codon 47correlates with ARV utilization
RM Kagan , M Shenderovich, K Ramnarayan, PNR Heseltine
PDF Poster

PDF POSTER
The 184A and 184C Mutations in Protease Confer High Level Resistance to PIs and Impair Replication Capacity
H Mo, N Parkin, K Stewart, et al.
PDF Poster

PDF POSTER
Exploring the Effects of Adherence on Resistance: Use of Local Linear Regression to Reveal Relationships Between Adherence and Resistance in Antiretroviral-Naive Patients Treated with Lopinavir/ritonavir or Nelfinavir
M King, S Brun, J Tschampa, et al
PDF Poster

PDF POSTER
Exploration of Methodology for Estimating Upper Clinical Breakpoints for Lopinavir/ritonavir by Analysis of the Emergence of Resistance During Virologic Failure in Experienced Patients
M King, H Mo, A Molla, et al
PDF Poster

PDF POSTER
The Impact of Minor Populations of Wild Type HIV on the Replication Capacity and Phenotype of Mutant Variants in a Single-cycle HIV Resistance Assay
H Mo, L Lu, D Kempf, A Molla, et al
Poster

    Tipranavir

PDF POSTER
Characterization of HIV-1 showing decreased susceptibility to tipranavir and their inhibition by tipranavir-containing drug mixtures
L Doyon, S Tremblay, E Wardrop, et al
PDF Poster

     Tenofovir

HIV DNA as a predictor of residual viraemia in patients treated with tenofovir+lamivudine+efavirenz or stavudine+lamivudine+efavirenz
DV Havlir, M Strain, MD Miller, et al.
Abstract


     Zidovudine

HIV-1 reverse transcriptase mutations that suppress zidovudine resistance also increase
in vitro susceptibility to tenofovir, but not stavudine
NT Parkin, C Chappey, CJ Petropoulos . N Hellmann
Abstract

Therapeutic HIV Drug Monitoring

POSTER
Correlation between Interpreted Genotype and Virtual Phenotype for predicting drug resistance in HIV-1
O Gallego, et al.
Poster

POSTER
Clinically relevant interpretation of genotype for resistance to ritonavir (100 mg twice daily) plus saquinavir (800 mg twice daily) in HIV-1-infected protease inhibitor-experienced patients
V Calvez, et al
Poster

POSTER
Genotypic associations with non-nucleoside reverse transcriptase inhibitor susceptibility in circulating recombinant forms of HIV-1 strains in North and South America
A Florance, et al
Poster

POSTER
Mutations at reverse transcriptase codon 103: phenotypic resistance to non-nucleoside reverse transcriptase inhibitor and clinical correlates
PR Harrigan, et al.
Poster

PDF POSTER
Clinician knowledge and attitudes towards genotypic testing
C Salama, et al.
PDF Poster

POSTER
Predictive value of drug resistance interpretation systems and therapeutic drug monitoring or virological therapy response to salvage therapy
H Walter, M Helm, R Ehret, er al.
Abstract

Treatment Interruption

PDF POSTER
Baseline resistance and predictors of virological response in the CPCRA 064 study: a randomized trial of structured treatment interruption for patients with multidrug-resistant HIV
J Lawrence, K. Huppler-Hullsiek, D Mayers. et al
PDF Poster

PDF POSTER
Resistance analysis of the benefit of a treatment interruption before salvage therapy including seven to nine antiretroviral drugs (GIGHAART ANRS 097)
C Delaugerre, S Dominguez, K. Gourlain, et al.
PDF Poster

Salvage Therapy

PDF POSTER
The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy
C Ciancio, MP Trotta, P. Lorenzini, et al.
PDF Poster

Untreated HIV

PDF POSTER
Persistence of multidrug-resistant HIV-1 without any antiretroviral treatment 2 years after sexual transmission
C Delaugerre, L Morand-Joubert, ML Chaix, et al.
PDF Poster

HIV Co-Infection/Superinfection

PDF POSTER
Population Genetics in HIV-1 Superinfection
S Parker, M Kearney, V Boltz, et al.
PDF Poster

Co- and super-infection: persistent replication of both HIV-1 strains?
L Perrin, S Yerly, M Monnat, et al Abstract

MSM

Drug resistance prevalence declines in recently infected subjects having sex with men
but not in those using drug injections: results from the Montreal Primary HIV-Infection Cohort
JP Routy, B Brenner, D Rouleau, et al.
Abstract

Main New/Newsworthy Conference Updates Home

XII International HIV Drug Resistance Workshop
Select Abstracts, Posters, and Reports
A Medical Advocates for Social Justice Update